The staffing challenges cancer centers are experiencing as a result of the pandemic are unprecedented. Cancer centers may need to develop new strategies to improve staff recruitment and retention in today’s environment.

With expanding treatment options, clinicians should understand important criteria used in selecting optimal first-and subsequent-line therapies for individuals with metastatic breast cancer. For clinicians, staying up to date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.

As a result of the therapeutic advances and clinical research affecting the management of patients with breast cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.

A number of new treatment options for different stages of bladder cancer are currently under investigation, which will make education important to cover the data behind these therapies and how they might be incorporated into future clinical practice. Of interest, treatment options for bacillus Calmette Guérin (BCG)-unresponsive non–muscle invasive bladder cancer are currently being evaluated in clinical trials as well as new systemic therapy options for muscle-invasive and metastatic disease.